Related references
Note: Only part of the references are listed.Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study
Michael P. Curry et al.
GASTROENTEROLOGY (2015)
Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
Michael Charlton et al.
GASTROENTEROLOGY (2015)
Sofosbuvir With Peginterferon-Ribavirin for 12 Weeks in Previously Treated Patients With Hepatitis C Genotype 2 or 3 and Cirrhosis
Eric Lawitz et al.
HEPATOLOGY (2015)
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
David R. Nelson et al.
HEPATOLOGY (2015)
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
Eric Lawitz et al.
LANCET (2015)
Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010
Maxine M. Denniston et al.
ANNALS OF INTERNAL MEDICINE (2014)
A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection
Fumitaka Suzuki et al.
ANTIVIRAL THERAPY (2014)
Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
Edward J. Gane et al.
GASTROENTEROLOGY (2014)
Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
Stefan Zeuzem et al.
GASTROENTEROLOGY (2014)
Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
Xavier Forns et al.
GASTROENTEROLOGY (2014)
Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population
Adriaan J. van der Meer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Natural history of hepatitis C
Rachel H. Westbrook et al.
JOURNAL OF HEPATOLOGY (2014)
Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C
Sonal Kumar et al.
JOURNAL OF HEPATOLOGY (2014)
Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation
Martina Gambato et al.
JOURNAL OF HEPATOLOGY (2014)
Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors
Tania Mara Welzel et al.
JOURNAL OF HEPATOLOGY (2014)
SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1-6 HCV INFECTION
G. T. Everson et al.
JOURNAL OF HEPATOLOGY (2014)
RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267+ABT-333+RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION
P. Kwo et al.
JOURNAL OF HEPATOLOGY (2014)
SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2014)
SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY
N. Afdhal et al.
JOURNAL OF HEPATOLOGY (2014)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns et al.
LANCET (2014)
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
Eric Lawitz et al.
LANCET (2014)
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Ira M. Jacobson et al.
LANCET (2014)
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
Michael Manns et al.
LANCET (2014)
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz et al.
LANCET (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targets for Antiviral Therapy of Hepatitis C
Daniel Rupp et al.
SEMINARS IN LIVER DISEASE (2014)
OPTN/SRTR 2011 Annual Data Report: Liver
W. R. Kim et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Homie Razavi et al.
HEPATOLOGY (2013)
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
Khayriyyah Mohd Hanafiah et al.
HEPATOLOGY (2013)
Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics A Randomized Clinical Trial
Anuoluwapo Osinusi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2013)
ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAIVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY
J. P. Lalezari et al.
JOURNAL OF HEPATOLOGY (2013)
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890
Christophe Hezode et al.
JOURNAL OF HEPATOLOGY (2013)
New therapeutic strategies in HCV: second-generation protease inhibitors
Virginia C. Clark et al.
LIVER INTERNATIONAL (2013)
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
Troels K. H. Scheel et al.
NATURE MEDICINE (2013)
Epidemiology and natural history of HCV infection
Behzad Hajarizadeh et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Ralf Bartenschlager et al.
NATURE REVIEWS MICROBIOLOGY (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Current and Future Therapies for Hepatitis C Virus Infection
T. Jake Liang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007
Kathleen N. Ly et al.
ANNALS OF INTERNAL MEDICINE (2012)
The role of resistance in HCV treatment
Johannes Vermehren et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2012)
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
Adriaan J. van der Meer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Antiviral strategies in hepatitis C virus infection
Christoph Sarrazin et al.
JOURNAL OF HEPATOLOGY (2012)
Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein
Oscar Belda et al.
VIRUS RESEARCH (2012)
A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C
Lisa I. Backus et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Telaprevir User's Guide
AnnMarie Liapakis et al.
CLINICS IN LIVER DISEASE (2011)
Retreatment with Telaprevir Combination Therapy in Hepatitis C Patients with Well-Characterized Prior Treatment Response
Andrew J. Muir et al.
HEPATOLOGY (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis
Hans-Heinrich Hoffmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Mechanism of Hepatitis C Virus RNA Polymerase Inhibition with Dihydroxypyrimidines
Megan H. Powdrill et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Factors That Determine the Development and Progression of Gastroesophageal Varices in Patients With Chronic Hepatitis C
Robert J. Fontana et al.
GASTROENTEROLOGY (2010)
A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin
Mark G. Swain et al.
GASTROENTEROLOGY (2010)
Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
Gary L. Davis et al.
GASTROENTEROLOGY (2010)
Twelve Weeks Posttreatment Follow-up Is as Relevant as 24 Weeks to Determine the Sustained Virologic Response in Patients with Hepatitis C Virus Receiving Pegylated Interferon and Ribavirin
Michelle Martinot-Peignoux et al.
HEPATOLOGY (2010)
Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
Savino Bruno et al.
HEPATOLOGY (2010)
Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B
Megan H. Powdrill et al.
VIRUSES-BASEL (2010)
Sustained Responders Have Better Quality of Life and Productivity Compared With Treatment Failures Long After Antiviral Therapy for Hepatitis C
Ava A. John-Baptiste et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression
Hla-Hla Thein et al.
HEPATOLOGY (2008)
Interaction of hepatitis c virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles
Takahiro Masaki et al.
JOURNAL OF VIROLOGY (2008)
Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly
Nicole Appel et al.
PLOS PATHOGENS (2008)
Regulation of hepatitis C virion production via phosphorylation of the NS5A protein
Timothy L. Tellinghuisen et al.
PLOS PATHOGENS (2008)
Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein
Timothy L. Tellinghuisen et al.
JOURNAL OF VIROLOGY (2008)
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
Bart J. Veldt et al.
ANNALS OF INTERNAL MEDICINE (2007)
Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis
Stuart Roberts et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study
Angelo Iacobellis et al.
JOURNAL OF HEPATOLOGY (2007)
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study
Savino Bruno et al.
HEPATOLOGY (2007)
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy
GT Everson et al.
HEPATOLOGY (2005)
Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival
Y Shiratori et al.
ANNALS OF INTERNAL MEDICINE (2005)
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
T Poynard et al.
GASTROENTEROLOGY (2002)
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation
JS Crippin et al.
LIVER TRANSPLANTATION (2002)
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis
A Gramenzi et al.
GUT (2001)
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
Y Shiratori et al.
ANNALS OF INTERNAL MEDICINE (2000)
Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines
B Wolk et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
